Kodiak Sciences Inc. announced that the first patient has been treated in the Phase 1 study of KSI-501, an investigational bispecific antibody biopolymer conjugate targeting both VEGF and IL-6. KSI-501 is the second product candidate built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform to enter the clinic. The Phase 1 study of KSI-501 is being conducted in the USA as an open-label, multiple ascending dose study and initially is enrolling patients with diabetic macular edema (DME). The primary objectives of the Phase 1 study are to evaluate ocular and systemic safety and to establish a maximum tolerated dose.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.26 USD | +1.56% | -12.83% | +7.24% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.24% | 171M | |
+9.99% | 115B | |
+12.01% | 106B | |
-3.07% | 24.69B | |
-0.70% | 21.97B | |
-4.50% | 19.27B | |
-6.90% | 17.56B | |
-39.36% | 17.32B | |
+5.82% | 14.03B | |
+33.05% | 12.13B |
- Stock Market
- Equities
- KOD Stock
- News Kodiak Sciences Inc.
- Kodiak Sciences Inc. Expands Development Pipeline with Treatment of First Patient in Phase 1 Clinical Study of KSI-501, an Investigational Bispecific Antibody Biopolymer Conjugate for Retinal Diseases